Neuroblastoma Clinical Trials in Georgia

Cancer Type = Neuroblastoma

Cancer Type = Neuroblastoma

There are currently 26 active Neuroblastoma clinical trials in Georgia.
1.
A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Lymphoma, Neuroblastoma
NCI ID
NCT03458728
Protocol IDs
19176
NCI-2018-00809
2017-000383-15
3.
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma
NCI ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
8.
A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed / Refractory Neuroblastoma
Cancer Type
Neuroblastoma
NCI ID
NCT03332667
Protocol IDs
NANT2017-01
NCI-2018-01160
9.
A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Liver/ Hepatoblastoma, Neuroblastoma, Rhabdomyosarcoma
NCI ID
NCT01956669
Protocol IDs
116731
NCI-2015-00058
11.
LEAHRN (Late Effects after High-Risk Neuroblastoma) Study
Cancer Type
Neuroblastoma
NCI ID
NCT03057626
Protocol IDs
ALTE15N2
ALTE15N2
COG-ALTE15N2
NCI-2017-00170
12.
N2004-05: Neuroblastoma Biology Study
Cancer Type
Neuroblastoma
NCI ID
NCT01587300
Protocol IDs
N2004-05
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
14.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Cancer Type
Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCI ID
NCT03698994
Protocol IDs
APEC1621J
APEC1621J
NCI-2018-02150
15.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1 / 2 / 3 / 4 Alterations
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03210714
Protocol IDs
APEC1621B
APEC1621B
NCI-2017-01159
16.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03213704
Protocol IDs
APEC1621A
APEC1621A
NCI-2017-01264
APEC1621A
17.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCI ID
NCT03526250
Protocol IDs
APEC1621I
APEC1621I
NCI-2018-00863
18.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
Cancer Type
Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03213691
Protocol IDs
APEC1621E
APEC1621E
NCI-2017-01250
APEC1621E
19.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03233204
Protocol IDs
APEC1621H
APEC1621H
NCI-2017-00766
APEC1621H
20.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
Cancer Type
Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03213652
Protocol IDs
APEC1621F
APEC1621F
NCI-2017-01243
APEC1621F
21.
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Unknown Primary
NCI ID
NCT03213678
Protocol IDs
APEC1621D
APEC1621D
NCI-2017-01249
APEC1621D
22.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Cancer Type
Bone and Soft Tissue (including Sarcoma), Brain Cancer , Ewing Sarcoma, Germ Cell Tumor, Liver/ Hepatoblastoma, Lymphoma, Neuroblastoma, Non-Hodgkin Lymphoma, Rhabdomyosarcoma, Unknown Primary
NCI ID
NCT03155620
Protocol IDs
APEC1621SC
APEC1621SC
NCI-2017-01251
APEC1621SC
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.